Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603218 | 0.88 | DRD2 (0.47) | SIGMAR1OPRM1OPRK1MEN1ALDH1A1 | |
| SCHEMBL6603813 | 0.86 | DRD3 (0.42) | SIGMAR1OPRM1 | |
| SCHEMBL6605765 | 0.67 | DRD2 (0.47) | SIGMAR1OPRM1MEN1ALDH1A1LMNA | |
| SCHEMBL6602182 | 0.67 | DRD2 (0.45) | OPRM1MEN1ALDH1A1KMT2A | |
| SCHEMBL6607339 | 0.65 | DRD3 (0.42) | SIGMAR1OPRM1 | |
| SCHEMBL8096481 | 0.65 | SIGMAR1 (1.00) | SIGMAR1KCNA3OPRM1 | |
| SCHEMBL7311113 | 0.65 | KCNA3 (0.71) | SIGMAR1KCNA3OPRM1 | |
| SCHEMBL9030344 | 0.64 | HRH3 (0.55) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL27789224 | 0.64 | SIGMAR1 (0.51) | SIGMAR1OPRM1OPRD1OPRK1MEN1 | |
| Hydrochloric Acid SCHEMBL2587759 | 0.64 | HTT (0.54) | SIGMAR1KCNA3OPRM1OPRD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1072601-B1 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6750231-B2 | SKIN DISORDERS; GASTROINTESTINAL DISORDERS | PFIZER INC | 2004-06-15 | — | — | US | disclosed |
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | GIBSON STEPHEN PAUL (GB) | 2003-01-02 | — | — | US | disclosed |
| EP-1072601-A2 | 4-arylpiperidine derivatives for the treatment of pruritus | PFIZER INC. (US) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004340-A1 | New 4-arylpiperidine derivatives for the treatment of pruritus | HRH2, HRH4, HRH1 | SIGMAR1 51/4885KCNA3 1114/4885OPRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.